Searched for
KEYTRUDA
Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...- India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Hospitals warn Central Government Health Scheme reimbursement cap may hurt cancer treatmentA major private hospital group warns of a crisis for advanced cancer patients under the Central Government Health Scheme. A reimbursement c...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Merck braces for Keytruda patent loss with $6.7 billion Terns betMerck is acquiring Terns Pharma for $6.7 billion to strengthen its cancer drug pipeline, aiming to reduce reliance on its blockbuster Keytr...
- Merck & Co to create a separate cancer unit as patent cliff loomsMerck & Co is restructuring by splitting its drug division into two separate businesses. The change is designed to spotlight its fastest-gr...
- Moderna shares up 2% as skin cancer vaccine shows sustained benefit in five-year follow-upModerna and Merck said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence of the most dea...
- Biocon Biologics to introduce three new biosimilars for cancer treatmentBiocon Biologics will launch three new oncology biosimilars. These include Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. The com...
- Dr Reddy’s, Alvotech to co-develop Keytruda biosimilarDr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a high...
- Dr. Reddy’s shares rise over 1% on strategic collaboration with Alvotech for Keytruda BiosimilarDr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of Keytruda (pembroli...
- Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatmentDr. Reddy's Laboratories has partnered with Alvotech to co-develop and commercialize a biosimilar for pembrolizumab (Keytruda), a crucial c...
- Dr Reddy’s shares climb over 4% after Keytruda biosimilar deal with AlvotechDr. Reddy’s shares rose over 4% after announcing a global biosimilar partnership with Alvotech for Keytruda. Q4FY25 profit rose 22% YoY to ...
- Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapyThe deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term focus on expe...
- You thought only DeepSeek routed American titans? Wait, here's a little-known Chinese biotech company whose lung cancer drug could rattle big pharma; here's all about itChinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This breakthrough si...
- Big chase for a cancer drug: The urgent need for affordable Keytruda alternativesKeytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In Ind...
- Daiichi Sankyo, Merck ink $22-billion cancer drug dealThe deal adds promising drug candidates to Merck's oncology portfolio, as its bestselling cancer therapy Keytruda will see its patent expir...
- mRNA technology-based Cancer vaccine boosts chances of survival: ModernaData revealed that using Merck's immunotherapy drug in combination with high-risk patients decreased their risk of dying.
- MSD launches blockbuster cancer drug Keytruda in IndiaDCGI gave MSD permission to market Keytruda in June 2016, according to minutes of the regulator’s Subject Expert Committee on oncology and ...
- Breakthrough cancer drugs all set for India launchThe accelerated regulatory clearances cut the time lines for introductions of the two big brands which may be expected to be introduced by ...
Load More
